Gerresheimer Ag · XETR:GXI
Gerresheimer — Merger or Acquisition (February 2008)
14 slides from Gerresheimer's merger presentation, Feb 4, 2008
Slide 1: Expansion Strategy: Gerresheimer Pharmaceutical Plastic Packaging and Preliminary Figures FY 2007
Expansion Strategy Gerresheimer Pharmaceutical Plastic Packaging and Preliminary Figures for the Fiscal Year 2007 February 4, 2008 Dr. Axel Herberg, CEO Hans-Jürgen Wiecha, CFO 1
Slide 2: Agenda
Agenda Expansion strategy Plastic Packaging Preliminary Figures FY 2007 2
Slide 3: Status Plastic Packaging End Of 2007
Status Plastic Packaging End Of 2007 Plastic Packaging had Net Sales of 53 m in 2007 The Plastic Packaging segment focuses on pharmaceutical containers for liquid and solid dose packaging Plastic Packaging holds the #1 market position in Europe Our production is organized within centres of competenc
Slide 4: Gerresheimer's acquisition strategy is based on clearly defined criteria
Gerresheimer’s acquisition strategy is based on clearly defined criteria Globalisation Targeted investments Organic Continuous productivity and growth quality improvement Further capitalise on leading Pharma/ market positions life science Global market Extension of product leadership Growth offering
Slide 5: Excellent fit of our recent acquisitions EDP and Allplas with the Plastic Packaging strategy
Excellent fit of our recent acquisitions EDP and Allplas with the Plastic Packaging strategy Regional expansion of pharmaceutical plastic packaging into Southern Europe and South America Extension of the Gerresheimer product offerings with PET-containers and of EDP/Allplas portfolio with Gerresheime
Slide 6: Short profile EDP
Short profile EDP Overview Transaction PET-containers, mainly for the Signing on December 21, 2007 pharmaceutical industry Closing on January 25, 2008 Leading market position in Spain Value-accretive in the first year and Argentina Two production sites in Zaragoza Next steps and Valencia, Spain and
Slide 7: Short profile Allplas
Short profile Allplas Overview Transaction Broad spectrum of containers and Signing on January 31, 2008 closures for the pharmaceutical Closing on January 31, 2008 industry Value-accretive in the first year Leading market position in Brazil 2 production sites in São Paulo, Next steps Brazil with a t
Slide 8: Plastic Packaging: Increase from 3 to 8 plants with pro-forma sales
Plastic Packaging: Increase from 3 to 8 plants with pro- forma sales of 7100 m Gerresheimer Vaerloese Gerresheimer Haarby Tablets & Powder Tablets & Powder Gerresheimer Sao Paulo Gerresheimer Boleslawiec Tablets & Powder Gerresheimer Droptainer Zaragoza PET-bottles Gerresheimer Buenos Aires Gerreshe
Slide 9: Agenda
Agenda Expansion strategy Plastic Packaging Preliminary Figures FY 2007 9
Slide 10: Preliminary Figures exactly meet our FY 2007 Guidance
Preliminary Figures exactly meet our FY 2007 Guidance1) Guidance Preliminary figures Organic growth2) : 8-9% Organic growth2) : 8.4% Net Sales Net sales: 957.7 m Growth: 48.1% Adjusted EBITDA Close to 19% 19.0% Margin 1) All figures on a preliminary basis. Final figures will be published on February
Slide 11: Preliminary Figures exactly meet our FY 2007 Guidance
Preliminary Figures exactly meet our FY 2007 Guidance1) Guidance Preliminary figures 95 - 100 m 98.9 m Major growth projects Completion of 2nd and down payment of 3rd RTF-syringe line Capex Building of a new production hall in the Czech Republic for insulin pens New production plant in China 7 sched
Slide 12: Financial Calendar 2007/2008
Financial Calendar 2007/2008 February 26, 2008 Full Year Results 2007 April 14, 2008 Interim Report 1st Quarter 2008 April 17, 2008 Annual General Meeting July 15, 2008 Interim Report 2nd Quarter 2008 October 15, 2008 Interim Report 3rd Quarter 2008 12
Slide 13: Contact Details
Contact Details Investor Relations Phone: +49 211 6181 314 Fax: +49 211 6181 121 Email: investorrelations@gerresheimer.com Please visit our IR website: www.gerresheimer.com/ir 13
Slide 14: Disclaimer
Disclaimer This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or